Salix Central
Overview
Artrya Salix is an AI-driven MedTech solution designed to assist physicians with cardiovascular diagnosis. It leverages machine learning to analyze cardiac computed tomography (CT) images, accurately assessing and detecting plaque features, stenosis, and calcification in real-time. The platform aims to significantly improve the speed and accuracy of Coronary Computed Tomography Angiography (CCTA) imaging reporting, reducing manual processing times and providing a comprehensive view of patient risk for coronary artery disease. Salix integrates with existing hospital imaging and patient management systems (PACS and EMR) to optimize clinical workflows and empower clinicians with better-informed diagnostic decisions. It is a web-based application intended as an adjunctive tool to complement standard care, not to replace a medical professional’s comprehensive diagnostic decision-making process.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- AI-driven analysis of cardiac CT images
- Accurate assessment and detection of plaque features (vulnerable plaque, low-attenuation plaque)
- Identification of stenosis and calcification
- Real-time or near real-time analysis (less than 10 minutes)
- Non-invasive diagnostic support
- Integration with existing hospital imaging and patient management systems (PACS and EMR)
- Automated workflow and diagnostic reporting
- Browser-based application
- Supports qualitative and quantitative assessment
- Potential for reduced reporting times (from 30 minutes to less than 2 minutes)
Use Cases
- Diagnosis of coronary artery disease (CAD)
- Assessment of high-risk plaques and coronary blood flow
- Improving speed and accuracy of CCTA imaging reporting
- Assisting physicians with cardiovascular diagnosis
- Accelerating triage of chest pain patients
- Optimizing clinical workflows
What Physicians Need to Know
Artrya Salix Central serves as a powerful adjunctive tool for cardiologists and radiologists, streamlining the diagnosis of coronary artery disease. It enables rapid and accurate identification of high-risk plaque features often missed by traditional methods, which can lead to more precise and personalized treatment plans. Physicians can leverage the detailed and standardized reports, including plaque volume and composition, to enhance communication with patients and referring physicians. The quick analysis time (around 10 minutes) can significantly improve workflow efficiency, accelerate patient triage, and potentially reduce unnecessary hospitalizations and prolonged diagnostic testing for chest pain patients. It is crucial for users to be appropriately trained in the software's functions, capabilities, and limitations, and to integrate its insights with their comprehensive clinical judgment and other patient information.
Artrya Salix Central is a cloud-based, AI-driven platform designed for seamless integration into existing healthcare IT infrastructure. It is compatible with standard CCTA scanners and processes images in DICOM format. The web-based application requires no capital equipment investment, downloads, installation, or hardware, making deployment simple. It integrates with hospital and clinic Picture Archiving and Communication Systems (PACS) and Electronic Medical Record (EMR) systems to optimize clinical workflows and facilitate collaborative care.
Details
| Category | Cardiology AI, Radiology & Imaging AI |
| Pricing | Contact for pricing |
| Deployment | Web-based software application; integrates with existing hospital and clinic imaging and patient management systems. |
| Compliance | |
| BAA Available | Unknown AI-estimated |
| HIPAA Compliant | Unknown AI-estimated |
| FDA Status |
1 AI-estimated Artrya Salix Central (K243038) received US FDA 510(k) clearance on March 27, 2025, as a web-based software for viewing, post-processing, and analyzing cardiac CT images, providing tools for qualitative and quantitative assessment of coronary plaques and stenosis in CCTA, and calcium scoring in non-contrast cardiac CT. The Salix Coronary Plaque module also received 510(k) clearance in August 2025, expanding the platform with automated low-attenuation plaque analysis. |
| Integrations | |
| EHR | Not specified |
| Specialties | Cardiology, Cardiothoracic Surgery, Radiology |
What the Web Says
Salix Central, a product by Artrya, generally receives positive to mixed reviews. It's recognized for its potential in cardiovascular AI and streamlining workflows, but some users note a learning curve and desire for more advanced features.
Overall: PositiveStrengths
- Potential for advanced cardiovascular AI diagnostics
- Aids in streamlining clinical workflows
- Integration capabilities with existing healthcare systems
- Aids in early disease detection and risk assessment
- User interface is generally considered intuitive after initial training
- Strong customer support noted in some reviews
Limitations
- Initial learning curve for new users
- Some physicians desire more customizable reporting features
- Integration challenges reported in some complex IT environments
- Cost can be a barrier for smaller practices
- Limited direct user reviews available on public platforms like G2/Capterra
- Specific advanced features are still under development or not yet widely adopted
Based on reviews from: Artrya Official Website, Healthcare IT News articles, Medical technology review sites, Physician forums and discussions (general sentiment), LinkedIn discussions (professional opinions), Academic papers and clinical studies referencing Artrya's technology
Last updated: 2026-07-17
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate Salix Central
Press & Coverage
Videos
Product demos, reviews, and walkthroughs for Salix Central.
Artrya brings AI-driven heart disease diagnostic tool to the US market with subsidiary spin off
Proactive Investors
